nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A5—Sorafenib—thyroid cancer	0.15	0.301	CbGbCtD
Rivaroxaban—ABCB1—Sorafenib—thyroid cancer	0.0977	0.196	CbGbCtD
Rivaroxaban—CYP3A4—Vandetanib—thyroid cancer	0.0971	0.195	CbGbCtD
Rivaroxaban—ABCB1—Doxorubicin—thyroid cancer	0.0593	0.119	CbGbCtD
Rivaroxaban—CYP3A4—Sorafenib—thyroid cancer	0.0585	0.117	CbGbCtD
Rivaroxaban—CYP3A4—Doxorubicin—thyroid cancer	0.0355	0.0713	CbGbCtD
Rivaroxaban—Haemorrhage—Vandetanib—thyroid cancer	0.00352	0.00702	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Vandetanib—thyroid cancer	0.00348	0.00693	CcSEcCtD
Rivaroxaban—Embolism venous—Epirubicin—thyroid cancer	0.00346	0.00691	CcSEcCtD
Rivaroxaban—Urethral disorder—Vandetanib—thyroid cancer	0.00345	0.00688	CcSEcCtD
Rivaroxaban—Pain in extremity—Sorafenib—thyroid cancer	0.00343	0.00685	CcSEcCtD
Rivaroxaban—Lactic dehydrogenase activity increased—Epirubicin—thyroid cancer	0.00342	0.00681	CcSEcCtD
Rivaroxaban—Erythema multiforme—Vandetanib—thyroid cancer	0.00333	0.00664	CcSEcCtD
Rivaroxaban—Eye disorder—Vandetanib—thyroid cancer	0.00329	0.00656	CcSEcCtD
Rivaroxaban—Cardiac disorder—Vandetanib—thyroid cancer	0.00327	0.00652	CcSEcCtD
Rivaroxaban—Embolism venous—Doxorubicin—thyroid cancer	0.00321	0.00639	CcSEcCtD
Rivaroxaban—Angiopathy—Vandetanib—thyroid cancer	0.0032	0.00637	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Vandetanib—thyroid cancer	0.00317	0.00633	CcSEcCtD
Rivaroxaban—Lactic dehydrogenase activity increased—Doxorubicin—thyroid cancer	0.00316	0.0063	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Sorafenib—thyroid cancer	0.00314	0.00625	CcSEcCtD
Rivaroxaban—Gingival bleeding—Epirubicin—thyroid cancer	0.00308	0.00614	CcSEcCtD
Rivaroxaban—Blood lactate dehydrogenase increased—Epirubicin—thyroid cancer	0.00301	0.006	CcSEcCtD
Rivaroxaban—Muscle spasms—Vandetanib—thyroid cancer	0.00295	0.00588	CcSEcCtD
Rivaroxaban—Gingival bleeding—Doxorubicin—thyroid cancer	0.00285	0.00568	CcSEcCtD
Rivaroxaban—Thrombocytosis—Epirubicin—thyroid cancer	0.00281	0.00561	CcSEcCtD
Rivaroxaban—Blood lactate dehydrogenase increased—Doxorubicin—thyroid cancer	0.00278	0.00555	CcSEcCtD
Rivaroxaban—Loss of consciousness—Vandetanib—thyroid cancer	0.00269	0.00537	CcSEcCtD
Rivaroxaban—Infestation NOS—Sorafenib—thyroid cancer	0.00265	0.00528	CcSEcCtD
Rivaroxaban—Infestation—Sorafenib—thyroid cancer	0.00265	0.00528	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00262	0.00523	CcSEcCtD
Rivaroxaban—Chest pain—Vandetanib—thyroid cancer	0.00261	0.0052	CcSEcCtD
Rivaroxaban—Thrombocytosis—Doxorubicin—thyroid cancer	0.0026	0.00519	CcSEcCtD
Rivaroxaban—Renal failure—Sorafenib—thyroid cancer	0.0026	0.00519	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00259	0.00517	CcSEcCtD
Rivaroxaban—Jaundice—Sorafenib—thyroid cancer	0.00258	0.00514	CcSEcCtD
Rivaroxaban—Dry mouth—Vandetanib—thyroid cancer	0.00255	0.00509	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Sorafenib—thyroid cancer	0.0025	0.00499	CcSEcCtD
Rivaroxaban—Oedema—Vandetanib—thyroid cancer	0.0025	0.00499	CcSEcCtD
Rivaroxaban—Epistaxis—Sorafenib—thyroid cancer	0.0025	0.00498	CcSEcCtD
Rivaroxaban—Infection—Vandetanib—thyroid cancer	0.00249	0.00496	CcSEcCtD
Rivaroxaban—Nervous system disorder—Vandetanib—thyroid cancer	0.00245	0.00489	CcSEcCtD
Rivaroxaban—Skin disorder—Vandetanib—thyroid cancer	0.00243	0.00485	CcSEcCtD
Rivaroxaban—Blister—Epirubicin—thyroid cancer	0.00243	0.00484	CcSEcCtD
Rivaroxaban—Haemoglobin—Sorafenib—thyroid cancer	0.00239	0.00476	CcSEcCtD
Rivaroxaban—Haemorrhage—Sorafenib—thyroid cancer	0.00238	0.00474	CcSEcCtD
Rivaroxaban—Haemoptysis—Epirubicin—thyroid cancer	0.00236	0.00471	CcSEcCtD
Rivaroxaban—Dermatitis atopic—Epirubicin—thyroid cancer	0.00236	0.00471	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Sorafenib—thyroid cancer	0.00235	0.00468	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Sorafenib—thyroid cancer	0.00233	0.00465	CcSEcCtD
Rivaroxaban—Urethral disorder—Sorafenib—thyroid cancer	0.00233	0.00464	CcSEcCtD
Rivaroxaban—Erythema multiforme—Sorafenib—thyroid cancer	0.00225	0.00448	CcSEcCtD
Rivaroxaban—Blister—Doxorubicin—thyroid cancer	0.00224	0.00447	CcSEcCtD
Rivaroxaban—Dyspnoea—Vandetanib—thyroid cancer	0.00223	0.00445	CcSEcCtD
Rivaroxaban—Cardiac disorder—Sorafenib—thyroid cancer	0.00221	0.0044	CcSEcCtD
Rivaroxaban—Dyspepsia—Vandetanib—thyroid cancer	0.0022	0.00439	CcSEcCtD
Rivaroxaban—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00219	0.00436	CcSEcCtD
Rivaroxaban—Haemoptysis—Doxorubicin—thyroid cancer	0.00219	0.00436	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00216	0.00431	CcSEcCtD
Rivaroxaban—Fatigue—Vandetanib—thyroid cancer	0.00216	0.0043	CcSEcCtD
Rivaroxaban—Angiopathy—Sorafenib—thyroid cancer	0.00216	0.0043	CcSEcCtD
Rivaroxaban—Immune system disorder—Sorafenib—thyroid cancer	0.00215	0.00428	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Sorafenib—thyroid cancer	0.00214	0.00427	CcSEcCtD
Rivaroxaban—Constipation—Vandetanib—thyroid cancer	0.00214	0.00427	CcSEcCtD
Rivaroxaban—Pain—Vandetanib—thyroid cancer	0.00214	0.00427	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00205	0.00408	CcSEcCtD
Rivaroxaban—Muscle spasms—Sorafenib—thyroid cancer	0.00199	0.00396	CcSEcCtD
Rivaroxaban—Abdominal pain—Vandetanib—thyroid cancer	0.00198	0.00394	CcSEcCtD
Rivaroxaban—Rectal haemorrhage—Epirubicin—thyroid cancer	0.00194	0.00386	CcSEcCtD
Rivaroxaban—Anaemia—Sorafenib—thyroid cancer	0.00191	0.00381	CcSEcCtD
Rivaroxaban—Angioedema—Sorafenib—thyroid cancer	0.00189	0.00377	CcSEcCtD
Rivaroxaban—Syncope—Sorafenib—thyroid cancer	0.00185	0.0037	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00185	0.00369	CcSEcCtD
Rivaroxaban—Loss of consciousness—Sorafenib—thyroid cancer	0.00182	0.00362	CcSEcCtD
Rivaroxaban—Asthenia—Vandetanib—thyroid cancer	0.0018	0.00358	CcSEcCtD
Rivaroxaban—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.00179	0.00357	CcSEcCtD
Rivaroxaban—Pruritus—Vandetanib—thyroid cancer	0.00177	0.00353	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00175	0.00349	CcSEcCtD
Rivaroxaban—Dry mouth—Sorafenib—thyroid cancer	0.00172	0.00343	CcSEcCtD
Rivaroxaban—Diarrhoea—Vandetanib—thyroid cancer	0.00171	0.00341	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00171	0.00341	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Sorafenib—thyroid cancer	0.00169	0.00337	CcSEcCtD
Rivaroxaban—Infection—Sorafenib—thyroid cancer	0.00168	0.00334	CcSEcCtD
Rivaroxaban—Shock—Sorafenib—thyroid cancer	0.00166	0.00331	CcSEcCtD
Rivaroxaban—Nervous system disorder—Sorafenib—thyroid cancer	0.00166	0.0033	CcSEcCtD
Rivaroxaban—Dizziness—Vandetanib—thyroid cancer	0.00165	0.0033	CcSEcCtD
Rivaroxaban—Blood urea increased—Epirubicin—thyroid cancer	0.00165	0.00329	CcSEcCtD
Rivaroxaban—Skin disorder—Sorafenib—thyroid cancer	0.00164	0.00327	CcSEcCtD
Rivaroxaban—Vomiting—Vandetanib—thyroid cancer	0.00159	0.00317	CcSEcCtD
Rivaroxaban—Ecchymosis—Epirubicin—thyroid cancer	0.00158	0.00315	CcSEcCtD
Rivaroxaban—Rash—Vandetanib—thyroid cancer	0.00158	0.00315	CcSEcCtD
Rivaroxaban—Dermatitis—Vandetanib—thyroid cancer	0.00158	0.00314	CcSEcCtD
Rivaroxaban—Headache—Vandetanib—thyroid cancer	0.00157	0.00313	CcSEcCtD
Rivaroxaban—Blood urea increased—Doxorubicin—thyroid cancer	0.00153	0.00305	CcSEcCtD
Rivaroxaban—Dyspnoea—Sorafenib—thyroid cancer	0.0015	0.003	CcSEcCtD
Rivaroxaban—Nausea—Vandetanib—thyroid cancer	0.00149	0.00296	CcSEcCtD
Rivaroxaban—Dyspepsia—Sorafenib—thyroid cancer	0.00149	0.00296	CcSEcCtD
Rivaroxaban—Ecchymosis—Doxorubicin—thyroid cancer	0.00146	0.00292	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00146	0.00291	CcSEcCtD
Rivaroxaban—Fatigue—Sorafenib—thyroid cancer	0.00146	0.0029	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00145	0.0029	CcSEcCtD
Rivaroxaban—Pain—Sorafenib—thyroid cancer	0.00144	0.00288	CcSEcCtD
Rivaroxaban—Constipation—Sorafenib—thyroid cancer	0.00144	0.00288	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00138	0.00275	CcSEcCtD
Rivaroxaban—Renal failure acute—Epirubicin—thyroid cancer	0.00137	0.00274	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00134	0.00268	CcSEcCtD
Rivaroxaban—Urticaria—Sorafenib—thyroid cancer	0.00134	0.00267	CcSEcCtD
Rivaroxaban—Abdominal pain—Sorafenib—thyroid cancer	0.00133	0.00266	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Epirubicin—thyroid cancer	0.00133	0.00265	CcSEcCtD
Rivaroxaban—Renal failure acute—Doxorubicin—thyroid cancer	0.00127	0.00254	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00127	0.00253	CcSEcCtD
Rivaroxaban—Pain in extremity—Epirubicin—thyroid cancer	0.00127	0.00253	CcSEcCtD
Rivaroxaban—Osteoarthritis—Epirubicin—thyroid cancer	0.00127	0.00253	CcSEcCtD
Rivaroxaban—Hypersensitivity—Sorafenib—thyroid cancer	0.00124	0.00248	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00123	0.00245	CcSEcCtD
Rivaroxaban—Asthenia—Sorafenib—thyroid cancer	0.00121	0.00241	CcSEcCtD
Rivaroxaban—Pruritus—Sorafenib—thyroid cancer	0.00119	0.00238	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Epirubicin—thyroid cancer	0.00119	0.00237	CcSEcCtD
Rivaroxaban—Osteoarthritis—Doxorubicin—thyroid cancer	0.00117	0.00234	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00117	0.00234	CcSEcCtD
Rivaroxaban—Pain in extremity—Doxorubicin—thyroid cancer	0.00117	0.00234	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Epirubicin—thyroid cancer	0.00116	0.00231	CcSEcCtD
Rivaroxaban—Diarrhoea—Sorafenib—thyroid cancer	0.00115	0.0023	CcSEcCtD
Rivaroxaban—Dizziness—Sorafenib—thyroid cancer	0.00112	0.00223	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Doxorubicin—thyroid cancer	0.0011	0.00219	CcSEcCtD
Rivaroxaban—Vomiting—Sorafenib—thyroid cancer	0.00107	0.00214	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00107	0.00214	CcSEcCtD
Rivaroxaban—Angina pectoris—Epirubicin—thyroid cancer	0.00107	0.00213	CcSEcCtD
Rivaroxaban—Rash—Sorafenib—thyroid cancer	0.00106	0.00212	CcSEcCtD
Rivaroxaban—Dermatitis—Sorafenib—thyroid cancer	0.00106	0.00212	CcSEcCtD
Rivaroxaban—Headache—Sorafenib—thyroid cancer	0.00106	0.00211	CcSEcCtD
Rivaroxaban—Nausea—Sorafenib—thyroid cancer	0.001	0.002	CcSEcCtD
Rivaroxaban—Angina pectoris—Doxorubicin—thyroid cancer	0.000989	0.00197	CcSEcCtD
Rivaroxaban—Infestation NOS—Epirubicin—thyroid cancer	0.000978	0.00195	CcSEcCtD
Rivaroxaban—Infestation—Epirubicin—thyroid cancer	0.000978	0.00195	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00097	0.00193	CcSEcCtD
Rivaroxaban—Renal failure—Epirubicin—thyroid cancer	0.000961	0.00192	CcSEcCtD
Rivaroxaban—Jaundice—Epirubicin—thyroid cancer	0.000953	0.0019	CcSEcCtD
Rivaroxaban—Urinary tract infection—Epirubicin—thyroid cancer	0.000951	0.0019	CcSEcCtD
Rivaroxaban—Haematuria—Epirubicin—thyroid cancer	0.000933	0.00186	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000925	0.00184	CcSEcCtD
Rivaroxaban—Epistaxis—Epirubicin—thyroid cancer	0.000923	0.00184	CcSEcCtD
Rivaroxaban—Sinusitis—Epirubicin—thyroid cancer	0.000918	0.00183	CcSEcCtD
Rivaroxaban—Agranulocytosis—Epirubicin—thyroid cancer	0.000913	0.00182	CcSEcCtD
Rivaroxaban—Infestation NOS—Doxorubicin—thyroid cancer	0.000905	0.0018	CcSEcCtD
Rivaroxaban—Infestation—Doxorubicin—thyroid cancer	0.000905	0.0018	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000897	0.00179	CcSEcCtD
Rivaroxaban—Renal failure—Doxorubicin—thyroid cancer	0.00089	0.00177	CcSEcCtD
Rivaroxaban—Haemoglobin—Epirubicin—thyroid cancer	0.000883	0.00176	CcSEcCtD
Rivaroxaban—Jaundice—Doxorubicin—thyroid cancer	0.000882	0.00176	CcSEcCtD
Rivaroxaban—Urinary tract infection—Doxorubicin—thyroid cancer	0.00088	0.00175	CcSEcCtD
Rivaroxaban—Haemorrhage—Epirubicin—thyroid cancer	0.000878	0.00175	CcSEcCtD
Rivaroxaban—Hepatitis—Epirubicin—thyroid cancer	0.000878	0.00175	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Epirubicin—thyroid cancer	0.000867	0.00173	CcSEcCtD
Rivaroxaban—Haematuria—Doxorubicin—thyroid cancer	0.000863	0.00172	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Epirubicin—thyroid cancer	0.000863	0.00172	CcSEcCtD
Rivaroxaban—Urethral disorder—Epirubicin—thyroid cancer	0.000861	0.00172	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000856	0.00171	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—thyroid cancer	0.000854	0.0017	CcSEcCtD
Rivaroxaban—Sinusitis—Doxorubicin—thyroid cancer	0.000849	0.00169	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—thyroid cancer	0.000845	0.00168	CcSEcCtD
Rivaroxaban—Erythema multiforme—Epirubicin—thyroid cancer	0.00083	0.00166	CcSEcCtD
Rivaroxaban—Eye disorder—Epirubicin—thyroid cancer	0.000821	0.00164	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—thyroid cancer	0.000817	0.00163	CcSEcCtD
Rivaroxaban—Cardiac disorder—Epirubicin—thyroid cancer	0.000815	0.00162	CcSEcCtD
Rivaroxaban—Haemorrhage—Doxorubicin—thyroid cancer	0.000812	0.00162	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—thyroid cancer	0.000812	0.00162	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000802	0.0016	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000798	0.00159	CcSEcCtD
Rivaroxaban—Angiopathy—Epirubicin—thyroid cancer	0.000797	0.00159	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—thyroid cancer	0.000796	0.00159	CcSEcCtD
Rivaroxaban—Immune system disorder—Epirubicin—thyroid cancer	0.000793	0.00158	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Epirubicin—thyroid cancer	0.000791	0.00158	CcSEcCtD
Rivaroxaban—Erythema multiforme—Doxorubicin—thyroid cancer	0.000768	0.00153	CcSEcCtD
Rivaroxaban—Eye disorder—Doxorubicin—thyroid cancer	0.000759	0.00151	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—thyroid cancer	0.000754	0.0015	CcSEcCtD
Rivaroxaban—Back pain—Epirubicin—thyroid cancer	0.000739	0.00147	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—thyroid cancer	0.000737	0.00147	CcSEcCtD
Rivaroxaban—Muscle spasms—Epirubicin—thyroid cancer	0.000735	0.00147	CcSEcCtD
Rivaroxaban—Immune system disorder—Doxorubicin—thyroid cancer	0.000734	0.00146	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000732	0.00146	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Epirubicin—thyroid cancer	0.000709	0.00141	CcSEcCtD
Rivaroxaban—Anaemia—Epirubicin—thyroid cancer	0.000706	0.00141	CcSEcCtD
Rivaroxaban—Malaise—Epirubicin—thyroid cancer	0.000689	0.00137	CcSEcCtD
Rivaroxaban—Syncope—Epirubicin—thyroid cancer	0.000685	0.00137	CcSEcCtD
Rivaroxaban—Back pain—Doxorubicin—thyroid cancer	0.000684	0.00136	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—thyroid cancer	0.00068	0.00136	CcSEcCtD
Rivaroxaban—Loss of consciousness—Epirubicin—thyroid cancer	0.000672	0.00134	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000656	0.00131	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—thyroid cancer	0.000654	0.0013	CcSEcCtD
Rivaroxaban—Chest pain—Epirubicin—thyroid cancer	0.000651	0.0013	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000646	0.00129	CcSEcCtD
Rivaroxaban—Discomfort—Epirubicin—thyroid cancer	0.000643	0.00128	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—thyroid cancer	0.000638	0.00127	CcSEcCtD
Rivaroxaban—Dry mouth—Epirubicin—thyroid cancer	0.000636	0.00127	CcSEcCtD
Rivaroxaban—Syncope—Doxorubicin—thyroid cancer	0.000634	0.00126	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Epirubicin—thyroid cancer	0.000624	0.00124	CcSEcCtD
Rivaroxaban—Oedema—Epirubicin—thyroid cancer	0.000624	0.00124	CcSEcCtD
Rivaroxaban—Loss of consciousness—Doxorubicin—thyroid cancer	0.000622	0.00124	CcSEcCtD
Rivaroxaban—Infection—Epirubicin—thyroid cancer	0.00062	0.00124	CcSEcCtD
Rivaroxaban—Shock—Epirubicin—thyroid cancer	0.000614	0.00122	CcSEcCtD
Rivaroxaban—Nervous system disorder—Epirubicin—thyroid cancer	0.000612	0.00122	CcSEcCtD
Rivaroxaban—Tachycardia—Epirubicin—thyroid cancer	0.000609	0.00121	CcSEcCtD
Rivaroxaban—Skin disorder—Epirubicin—thyroid cancer	0.000606	0.00121	CcSEcCtD
Rivaroxaban—Chest pain—Doxorubicin—thyroid cancer	0.000602	0.0012	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000598	0.00119	CcSEcCtD
Rivaroxaban—Discomfort—Doxorubicin—thyroid cancer	0.000595	0.00119	CcSEcCtD
Rivaroxaban—Dry mouth—Doxorubicin—thyroid cancer	0.000589	0.00117	CcSEcCtD
Rivaroxaban—Hypotension—Epirubicin—thyroid cancer	0.000583	0.00116	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000577	0.00115	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—thyroid cancer	0.000577	0.00115	CcSEcCtD
Rivaroxaban—Infection—Doxorubicin—thyroid cancer	0.000573	0.00114	CcSEcCtD
Rivaroxaban—Shock—Doxorubicin—thyroid cancer	0.000568	0.00113	CcSEcCtD
Rivaroxaban—Nervous system disorder—Doxorubicin—thyroid cancer	0.000566	0.00113	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—thyroid cancer	0.000563	0.00112	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—thyroid cancer	0.000561	0.00112	CcSEcCtD
Rivaroxaban—Dyspnoea—Epirubicin—thyroid cancer	0.000556	0.00111	CcSEcCtD
Rivaroxaban—Dyspepsia—Epirubicin—thyroid cancer	0.000549	0.00109	CcSEcCtD
Rivaroxaban—Hypotension—Doxorubicin—thyroid cancer	0.000539	0.00108	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000539	0.00107	CcSEcCtD
Rivaroxaban—Fatigue—Epirubicin—thyroid cancer	0.000538	0.00107	CcSEcCtD
Rivaroxaban—Constipation—Epirubicin—thyroid cancer	0.000533	0.00106	CcSEcCtD
Rivaroxaban—Pain—Epirubicin—thyroid cancer	0.000533	0.00106	CcSEcCtD
Rivaroxaban—Dyspnoea—Doxorubicin—thyroid cancer	0.000515	0.00103	CcSEcCtD
Rivaroxaban—Feeling abnormal—Epirubicin—thyroid cancer	0.000514	0.00102	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00051	0.00102	CcSEcCtD
Rivaroxaban—Dyspepsia—Doxorubicin—thyroid cancer	0.000508	0.00101	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000498	0.000994	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—thyroid cancer	0.000498	0.000992	CcSEcCtD
Rivaroxaban—Urticaria—Epirubicin—thyroid cancer	0.000496	0.000988	CcSEcCtD
Rivaroxaban—Pain—Doxorubicin—thyroid cancer	0.000494	0.000984	CcSEcCtD
Rivaroxaban—Constipation—Doxorubicin—thyroid cancer	0.000494	0.000984	CcSEcCtD
Rivaroxaban—Abdominal pain—Epirubicin—thyroid cancer	0.000493	0.000983	CcSEcCtD
Rivaroxaban—Feeling abnormal—Doxorubicin—thyroid cancer	0.000476	0.000948	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000472	0.000941	CcSEcCtD
Rivaroxaban—Hypersensitivity—Epirubicin—thyroid cancer	0.00046	0.000916	CcSEcCtD
Rivaroxaban—Urticaria—Doxorubicin—thyroid cancer	0.000459	0.000914	CcSEcCtD
Rivaroxaban—Abdominal pain—Doxorubicin—thyroid cancer	0.000456	0.00091	CcSEcCtD
Rivaroxaban—Asthenia—Epirubicin—thyroid cancer	0.000448	0.000892	CcSEcCtD
Rivaroxaban—Pruritus—Epirubicin—thyroid cancer	0.000441	0.00088	CcSEcCtD
Rivaroxaban—Diarrhoea—Epirubicin—thyroid cancer	0.000427	0.000851	CcSEcCtD
Rivaroxaban—Hypersensitivity—Doxorubicin—thyroid cancer	0.000425	0.000848	CcSEcCtD
Rivaroxaban—Asthenia—Doxorubicin—thyroid cancer	0.000414	0.000826	CcSEcCtD
Rivaroxaban—Dizziness—Epirubicin—thyroid cancer	0.000413	0.000822	CcSEcCtD
Rivaroxaban—Pruritus—Doxorubicin—thyroid cancer	0.000408	0.000814	CcSEcCtD
Rivaroxaban—Vomiting—Epirubicin—thyroid cancer	0.000397	0.000791	CcSEcCtD
Rivaroxaban—Diarrhoea—Doxorubicin—thyroid cancer	0.000395	0.000787	CcSEcCtD
Rivaroxaban—Rash—Epirubicin—thyroid cancer	0.000393	0.000784	CcSEcCtD
Rivaroxaban—Dermatitis—Epirubicin—thyroid cancer	0.000393	0.000783	CcSEcCtD
Rivaroxaban—Headache—Epirubicin—thyroid cancer	0.000391	0.000779	CcSEcCtD
Rivaroxaban—Dizziness—Doxorubicin—thyroid cancer	0.000382	0.000761	CcSEcCtD
Rivaroxaban—Nausea—Epirubicin—thyroid cancer	0.000371	0.000739	CcSEcCtD
Rivaroxaban—Vomiting—Doxorubicin—thyroid cancer	0.000367	0.000732	CcSEcCtD
Rivaroxaban—Rash—Doxorubicin—thyroid cancer	0.000364	0.000726	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—thyroid cancer	0.000364	0.000725	CcSEcCtD
Rivaroxaban—Headache—Doxorubicin—thyroid cancer	0.000362	0.000721	CcSEcCtD
Rivaroxaban—Nausea—Doxorubicin—thyroid cancer	0.000343	0.000684	CcSEcCtD
